|
Pyrosequencing Inc
solid phase pyrosequencing Solid Phase Pyrosequencing, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/deep-sequencing+raw+data/phase+pyrosequencing+solid/10__1101_slash_gr__150601-111-1-14 Average 86 stars, based on 1 article reviews
solid phase pyrosequencing - by Bioz Stars,
2026-10
86/100 stars
|
Buy from Supplier |
|
10X Genomics
package cellranger Package Cellranger, supplied by 10X Genomics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/deep-sequencing+raw+data/cellranger/10__7554_slash_elife__32303-357-13-10 Average 86 stars, based on 1 article reviews
package cellranger - by Bioz Stars,
2026-10
86/100 stars
|
Buy from Supplier |
|
Illumina Inc
hiseq 2500 ![]() Hiseq 2500, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/deep-sequencing+raw+data/HiSeq+2500+Installation+and+Operational+Qualification/pmc08428355-106-11-10 Average 98 stars, based on 1 article reviews
hiseq 2500 - by Bioz Stars,
2026-10
98/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cancers
Article Title: Immune-Omics Networks of CD27 , PD1 , and PDL1 in Non-Small Cell Lung Cancer
doi: 10.3390/cancers13174296
Figure Lengend Snippet: The 5-gene prognostic model for NSCLC. ( A ) Kaplan–Meier analysis of patients grouped by risk-scores with the cutoff value of 2.25 in GSE81089. ( B ) Kaplan–Meier analysis of patients stratified by risk-scores with the cutoff value of 2.25 in TCGA-LUSC and TCGA-LUAD. The plot shows the results of first 10 years after surgery. ( C ) Genes associated with radiotherapy response. These genes had a significant differential expression ( p < 0.05, two-sample t -tests) in the long survival group versus the short survival group in TCGA-LUSC and TCGA-LUAD. Stage III or IV patients who had received radiotherapy were included in the analysis. FC: fold change of gene expression in the long survival versus the short survival patient group.
Article Snippet: Deep RNA sequencing of the patient tumors was generated with
Techniques: Expressing